Paris—Dentons Paris advised Laboratoires Expanscience on the acquisition of Medtech Sublimed, which develops medical devices for managing chronic pain. Historically specializing in the development of dermo-cosmetic products (Mustela), natural cosmetic active ingredients and rheumatology, Laboratoires Expanscience had a turnover of €324 million in 2022, 77% of which was generated internationally.

This acquisition enriches Laboratoires Expanscience’s portfolio of products for the treatment of osteoarthritis and allows it to diversify its expertise in research and development, as well as to develop its rheumatology business in the United States.

This agreement follows an ongoing collaboration between the two companies. Initiated in 2016 as part of Expanscience's open innovation approach, it resulted in the development and marketing of VitaliTENS, as a non-drug analgesic alternative.

Laboratoires Expanscience is a long-standing client of Dentons' Paris office. In 2018, Pascal Chadenet had already assisted the group in the acquisition of Babo Botanicals in the United States.

The Dentons Paris M&A team consisted of partner Pascal Chadenet and associate Imane Sayah.

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com